- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00701077
DAPERB 3,4-DiAminoPyridine and Electrophysiological Response in Brugada Syndrome (DAPREB)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background:
The Brugada syndrome is a rare disease potentially leading to severe arrhythmic events in otherwise healthy subjects.In many patients an Implantable cardiovertor defibrillator (ICD) is implanted to prevent sudden cardiac death. ICD are however associated with potential complications and are not available in all countries.Pharmacological blockade of specific ion channels (Ito) represents a promising therapeutic approach in this syndrome. Experimental data show that increased Ito current may be associated with both the ECG feature and arrhythmogenic substrate observed in the syndrome. Moreover, Ito blockade reverse the ECG abnormalities and suppress arrhythmogenicity.The 3,4-diaminopyridine (3,4-DAP) is a pharmacological Ito blocker that is already used in humans for another indication.
Main objective:
The aim of the study is to evaluate the effect of 3,4-DAP on ventricular arrhythmia inducibility in Brugada patients requiring an electrophysiological study for arrhythmic risk stratification.
First end point:
Re-inducibility or non re-inducibility of sustained ventricular arrhythmia during electrophysiological study on treatment
Tested hypothesis:
The 3,4-DAP decreases the proportion of re-inducibility during the electrophysiological study with a re-inducibility rate of 80% in the placebo group and 25% in the 3,4-DAP group
Secondary objective:
- to assess the effect of 3,4-DAP on ST segment elevation in Brugada patients
- to describe the relationship between 3,4-DAP plasma concentration measured at 45 minutes and electrophysiological study result and ST segment elevation
Study design:
2 centres, randomised, double blind, parallel groups, placebo controlledA single dose of 20 mg of 3,4-DAP
Included patients and number of patients:
Included patients will all have a diagnosed Brugada type 1 ECG and will require an electrophysiological study for arrhythmic risk stratification purpose. Only inducible patients will be included in the study.Using a classical approach, the hypothesis would be that 80% of on placebo patients would be re-inducible when only 25% of on drug patients would. To test such an hypothesis, 32 patients (16 in each group) would have been necessary (a=5%, b=20%).Provided the essential binary response of the electrophysiological study we choose a sequential approach in order to get the opportunity stop for success or futility the inclusions before the end of the study. The maximum number of included patients will then be 42 (21 in each group).
Protocol duration:
Study duration is 48 hours for each patient.The protocol duration is planned for 5 years.
Per protocol procedures:
- Electrophysiological study with ventricular programmed stimulation performed twice
- Continuous ECG recording- Blood sampling for 3,4-DAP plasma concentration measurement Potential implications:If the study hypotheses are confirmed it would then be justified to design long term efficacy studies in Brugada patients implanted with an ICD.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Paris, France, 75010
- Lariboisière University Hospital - Cardiology department
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Man or woman ≥ 18 years old
- Brugada syndrome diagnosed with a type 1 ECG either spontaneous or drug-induced
- Electrophysiological study indicated for arrhythmic risk stratification purpose
- Inducibility of a sustained ventricular tachycardia (> 30 seconds) or ventricular fibrillation requiring defibrillation
- Physical medical examination
- Signed written informed consent
Exclusion Criteria:
- Personal or familial history of epilepsy
- Pregnancy
- Body weight > 100 kg
- the need of >1 counter shock for defibrillation
- Alcohol or cocaine consumption during the protocol
- Class I (with the exception of local anaesthesia by lidocaine), II, III and IV antiarrhythmic drugs, antidepressant drugs, ATP dependent potassium channel activators, sultopride not stopped for > 7 halve-lives
- No medical insurance
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
PLACEBO_COMPARATOR: 2
|
placebo
|
EXPERIMENTAL: 1
3,4-Di-amino-Pyridine : a single 20 mg dosing
|
a single 20 mg dosing
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Electrophysiological study result (re-inducibility or not) 45 minutes after drug intake
Time Frame: 45 minutes after drug intake
|
45 minutes after drug intake
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
the effect of 3,4-DAP on ST segment elevation in Brugada patients (45 minutes)
Time Frame: at 45 minutes
|
at 45 minutes
|
the relationship between 3,4-DAP plasma concentration measured at 45 minutes and electrophysiological study result and ST segment elevation
Time Frame: at 45 minutes
|
at 45 minutes
|
Collaborators and Investigators
Investigators
- Principal Investigator: Fabrice EXTRAMIANA, MD, PhD, Lariboisière University Hospital - Cardiology department
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- P060802
- EUDRACT 2007-004133-42
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Brugada Syndrome
-
Istituto di Fisiologia Clinica CNRAzienda Ospedaliero, Universitaria Pisana; Azienda USL Toscana Nord Ovest; Azienda... and other collaboratorsNot yet recruitingBrugada Syndrome 1Italy
-
Hospices Civils de LyonUnknownBrugada Syndrome Type 1France
-
Angelo AuricchioTerminatedBrugada Syndrome 1SBelgium, Italy, Switzerland
-
Universitair Ziekenhuis BrusselNot yet recruitingNo Specific Condition (Patients Without Brugada Syndrome)Belgium
-
Assiut UniversityNot yet recruitingBrugada ECG Patterns
-
IRCCS Policlinico S. DonatoRecruitingECG Brugada PatternItaly
-
Universitair Ziekenhuis BrusselRecruiting
-
Pacific Rim Electrophysiology Research InstituteAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)RecruitingBrugada SyndromeThailand, Netherlands
-
Abbott Medical DevicesCompleted
-
Universitair Ziekenhuis BrusselUnknown
Clinical Trials on placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States